BACKGROUND: Prevalence of methicillin-resistant Staphylococcus aureus (MRSA) and interchange of hospital-associated strains carrying the staphylococcal chromosomal cassette mec-II (SCCmec-II) with those in the community (SCCmec-IV) has increased. This study assesses the impact of MRSA and different MRSA types on clinical outcomes, medication use, and antibiotic sensitivities. METHODS: MRSA isolates from CF patients at our center were typed by SCCmec- and pv(l) status. Patient characteristics, lung function and nutrition are compared between MRSA types and to age, gender and Pseudomonas aeruginosa matched patients with chronic methicillin sensitive S. aureus (MSSA) infection. RESULTS: Seventy-two percent of patients carry pv(l) negative SCCmec-II isolates. Seventeen percent of all MRSA were SCCmec-IV pv(l) positive (USA300). These patients were younger and fewer had chronic P. aeruginosa infection, whereas pv(l)-negative SCCmec-IV isolates show highest antibiotic resistance. Nutritional outcomes and FEV1 percent predicted (75.1 ± 2.7 versus 77.9 ± 2.7) did not differ in patients with MRSA compared to those with MSSA but MRSA patients received more pulmonary maintenance but not oral antibiotic medications. CONCLUSION: Patients with chronic MRSA are treated more intensely than age, gender and Pseudomonas aeruginosa matched MSSA-positive patients but clinical characteristics within MRSA patients vary depending on MRSA types.
BACKGROUND: Prevalence of methicillin-resistant Staphylococcus aureus (MRSA) and interchange of hospital-associated strains carrying the staphylococcal chromosomal cassette mec-II (SCCmec-II) with those in the community (SCCmec-IV) has increased. This study assesses the impact of MRSA and different MRSA types on clinical outcomes, medication use, and antibiotic sensitivities. METHODS: MRSA isolates from CFpatients at our center were typed by SCCmec- and pv(l) status. Patient characteristics, lung function and nutrition are compared between MRSA types and to age, gender and Pseudomonas aeruginosa matched patients with chronic methicillin sensitive S. aureus (MSSA) infection. RESULTS: Seventy-two percent of patients carry pv(l) negative SCCmec-II isolates. Seventeen percent of all MRSA were SCCmec-IV pv(l) positive (USA300). These patients were younger and fewer had chronic P. aeruginosa infection, whereas pv(l)-negative SCCmec-IV isolates show highest antibiotic resistance. Nutritional outcomes and FEV1 percent predicted (75.1 ± 2.7 versus 77.9 ± 2.7) did not differ in patients with MRSA compared to those with MSSA but MRSA patients received more pulmonary maintenance but not oral antibiotic medications. CONCLUSION:Patients with chronic MRSA are treated more intensely than age, gender and Pseudomonas aeruginosa matched MSSA-positive patients but clinical characteristics within MRSA patients vary depending on MRSA types.
Authors: Gabriela R Oates; William T Harris; Steven M Rowe; George M Solomon; Suranjana Dey; Aowen Zhu; Wynton C Hoover; Hector H Gutierrez Journal: Pediatr Infect Dis J Date: 2019-11 Impact factor: 2.129
Authors: Marianne Sponer Muhlebach; Valeria Beckett; Elena Popowitch; Melissa B Miller; Arthur Baines; Nicole Mayer-Hamblett; Edith T Zemanick; Wynton C Hoover; Jill M VanDalfsen; Preston Campbell; Christopher H Goss Journal: Thorax Date: 2016-11-15 Impact factor: 9.139
Authors: Marianne S Muhlebach; Sonya L Heltshe; Elena B Popowitch; Melissa B Miller; Valeria Thompson; Margaret Kloster; Thomas Ferkol; Wynton C Hoover; Michael S Schechter; Lisa Saiman Journal: Ann Am Thorac Soc Date: 2015-06
Authors: Elizabeth L Salsgiver; Aliza K Fink; Emily A Knapp; John J LiPuma; Kenneth N Olivier; Bruce C Marshall; Lisa Saiman Journal: Chest Date: 2016-01-12 Impact factor: 9.410
Authors: Harry S Porterfield; Lucas J Maakestad; Mason M LaMarche; Andrew L Thurman; Zoe E Kienenberger; Nicholas J Pitcher; Alexis R Hansen; Christian F Zirbes; Linda Boyken; Bethany L Muyskens; Alejandro A Pezzulo; Sachinkumar B Singh; Erik Twait; Bradley Ford; Daniel J Diekema; Valérie Reeb; Anthony J Fischer Journal: Pediatr Pulmonol Date: 2021-07-16